These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33620439)

  • 1. Association between β-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry.
    Mars K; Wallert J; Held C; Humphries S; Pingel R; Jernberg T; Olsson EMG; Hofmann R
    Eur Heart J Acute Cardiovasc Care; 2021 May; 10(4):372-379. PubMed ID: 33620439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
    Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study.
    Andell P; Erlinge D; Smith JG; Sundström J; Lindahl B; James S; Koul S
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25854796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.
    Goldberger JJ; Bonow RO; Cuffe M; Liu L; Rosenberg Y; Shah PK; Smith SC; Subačius H;
    J Am Coll Cardiol; 2015 Sep; 66(13):1431-41. PubMed ID: 26403339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients.
    Shavadia JS; Holmes DN; Thomas L; Peterson ED; Granger CB; Roe MT; Wang TY
    Circ Cardiovasc Qual Outcomes; 2019 Jul; 12(7):e005103. PubMed ID: 31284739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
    Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
    Trials; 2020 May; 21(1):415. PubMed ID: 32446298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-blockers after myocardial infarction and 1-year clinical outcome - a retrospective study.
    Hagsund T; Olsson SE; Smith JG; Madsen Hardig B; Wagner H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):165. PubMed ID: 32272880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
    Andersson C; Mérie C; Jørgensen M; Gislason GH; Torp-Pedersen C; Overgaard C; Køber L; Jensen PF; Hlatky MA
    JAMA Intern Med; 2014 Mar; 174(3):336-44. PubMed ID: 24247428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
    Kim J; Kang D; Park H; Kang M; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Guallar E; Cho J; Hahn JY
    Eur Heart J; 2020 Oct; 41(37):3521-3529. PubMed ID: 32542362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Year Landmark Analysis of the Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.
    Goldberger JJ; Subačius H; Marroquin OC; Beau SL; Simonson J;
    J Am Heart Assoc; 2021 Jul; 10(14):e019017. PubMed ID: 34227397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
    Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Li C; Sun Y; Shen X; Yu T; Li Q; Ruan G; Zhang L; Huang Q; Zhuang H; Huang J; Ni L; Wang L; Jiang J; Wang Y; Wang DW
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27852588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.
    Sorbets E; Steg PG; Young R; Danchin N; Greenlaw N; Ford I; Tendera M; Ferrari R; Merkely B; Parkhomenko A; Reid C; Tardif JC; Fox KM;
    Eur Heart J; 2019 May; 40(18):1399-1407. PubMed ID: 30590529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between β-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study.
    Humphries S; Wallert J; Mars K; Held C; Hofmann R; Olsson EMG
    Eur Heart J Acute Cardiovasc Care; 2022 Jun; 11(6):491-500. PubMed ID: 35510962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
    Ozasa N; Morimoto T; Bao B; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tazaki J; Natsuaki M; Kimura T;
    Int J Cardiol; 2013 Sep; 168(2):774-9. PubMed ID: 23127614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study.
    Lindgren M; Nielsen SJ; Björklund E; Pivodic A; Perrotta S; Hansson EC; Jeppsson A; Martinsson A
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):529-536. PubMed ID: 35102367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry.
    Chung J; Han JK; Yang HM; Park KW; Kang HJ; Koo BK; Jeong MH; Kim HS;
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S62-S71. PubMed ID: 32615654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
    Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Beta-Blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review.
    Hong J; Barry AR
    Pharmacotherapy; 2018 May; 38(5):546-554. PubMed ID: 29601115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.